A Review on Documentation and Record Management in the Pharmaceutical Industry

Documentation:

A document refers to any written record or proof. Documentation serves as a vital element of both the Quality Assurance (QA) and Quality Control (QC) systems and is closely associated with all aspects of Good Manufacturing Practices (GMP). It primarily outlines the specifications for materials, manufacturing methods, and control procedures. Additionally, it ensures that all personnel involved in production have the necessary information to determine whether a batch should be released for sale. Documentation also provides an audit trail, enabling the investigation of any potentially defective batch.

Purpose of Documentation:

• Provides written evidence, traceability, and records, creating an audit trail for investigation.
• Ensures the availability of data required for validation, review, and statistical evaluation.
• Establishes clear specifications and procedures for materials, manufacturing, and control methods.
• Ensures that all staff members are aware of their responsibilities and timing of activities.
• Provides authorized personnel with complete and accurate information necessary for product release.

The pharmaceutical industry has shifted from paper-based to digital documentation for marketing authorization dossiers, emphasizing the need for long-term or permanent recordkeeping and the competencies required for managing digital records.

Proper documentation, including the Master Formula Record (MFR), Batch Manufacturing Record (BMR), and Standard Operating Procedures (SOPs), forms the foundation of the pharmaceutical quality management system. These documents are essential for maintaining uniformity in manufacturing, meeting regulatory guidelines, and ensuring complete traceability of each batch. They serve as official records that guide formulation, processing, and quality control, thus supporting compliance with Good Manufacturing Practices (GMP) and facilitating audits, process validation, and continual quality improvement.

Good Documentation Practices (GDP):

In the pharmaceutical industry, Good Documentation Practices (GDP or GDocP) refer to the principles that ensure the accuracy, reliability, and integrity of data recorded throughout the processes of drug development, registration, manufacturing, commercialization, and lifecycle management. Adhering to GDP minimizes errors during manufacturing and analysis, thereby protecting product quality, patient safety, and maintaining proper operational standards within manufacturing facilities. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate compliance with GDP through guidelines like the FDA’s Code of Federal Regulations (CFR) and the European EudraLex. Additionally, the United States Pharmacopeia (USP) has issued general chapter <1029> on GDP, while other organizations, including the World Health Organization (WHO) and Health Canada, have also provided specific guidance. In the U.S., GDP is a key component of the Current Good Manufacturing Practices (cGMPs) framework.

Definition:

Good Documentation Practice (GDP) refers to the standards governing the preparation, maintenance, and management of documentation within the pharmaceutical sector. While some standards are set by the FDA, others are defined under cGMP regulations. Compliance with GDP is mandatory for pharmaceutical, biotechnology, and healthcare companies—as well as their suppliers—to avoid penalties and regulatory actions.

According to the WHO, the main purposes of GDP are to:

• Provide clear guidelines for creating, reviewing, approving, maintaining, correcting, verifying, and archiving documents.
• Ensure that all personnel involved in production understand their duties and the appropriate timing of actions.
• Guarantee that authorized personnel possess complete information to make decisions on product batch release.
• Maintain documented evidence, traceability, and records that enable effective investigation and audits.
• Ensure the availability of data for validation, evaluation, and statistical review.
• Define specifications and procedures for all manufacturing and control operations.
• Enhance operational efficiency and performance.
• Fulfill international and national regulatory requirements.

Objectives:

• To establish, monitor, and record all activities that directly or indirectly influence the quality of pharmaceutical products.
• To apply appropriate documentation standards depending on the document type.
• To ensure that documents remain accurate, complete, readable, and accessible throughout their lifecycle.
• To maintain error-free records, and in cases where corrections are necessary, ensure they are made with proper justification, signature, and date.
• To define the term “written” as any data recorded in a format that can be read and interpreted by humans.
• To prepare a Site Master File, which outlines the manufacturer’s GMP-related operations and activities.

General Requirements:

1. Good documentation is a fundamental component of the quality assurance system.
2. Clearly written procedures help prevent mistakes that can occur through verbal communication, while proper documentation allows for tracking and verification of activities performed.
3. All documents should be carefully designed, prepared, reviewed, and distributed to ensure accuracy and reliability.
4. Each document must be reviewed, approved, signed, and dated by authorized and qualified personnel.
5. Documents should have clear, specific, and unambiguous content. Their title, purpose, and type must be explicitly stated. They should be well-organized, easy to verify, and all copies must be legible and clear.
6. Documents must be reviewed regularly and updated as needed. A proper control system should ensure that outdated or superseded versions are not used and that only the current, approved versions are available.
7. Documents should not be handwritten; however, when information such as dates or signatures must be entered manually, it should be done clearly in permanent ink (not pencil). Adequate space should be provided for these entries.
8. Any corrections made in a document or record should include the signature or initials and date of the person making the change. The original entry must remain visible, and where applicable, the reason for the correction should also be documented.

Master Formula Record (MFR)    

The Master Formula Record (MFR) is one of the most essential documents in the pharmaceutical industry. It serves as the “master recipe” for the preparation of a drug product and contains detailed instructions on how each batch of medicine should be manufactured. The pharmaceutical industry is highly regulated, and no product can be manufactured without proper documentation. Among the documentation practices, the Master Formula Record plays a critical role in ensuring that every batch produced is consistent, safe, effective, and compliant with regulatory guidelines. The Master Formula Record (MFR) is a comprehensive document that specifies the formulation composition, list of raw materials, quantities,   equipment  required, and detailed manufacturing instructions. For SR formulations, the MFR also includes details about the polymer system or coating materials responsible for controlling the drug release rate. The MFR is prepared by the formulation development team and approved by the Quality Assurance (QA) department. Once approved, it acts as a reference for the preparation of Batch Manufacturing Records (BMR) and guides operators, supervisors, and quality control personnel during the production process. It acts as the foundation of Good Manufacturing Practices (GMP) because it provides step-by-step details of how a pharmaceutical product should be made, tested, packaged, and labeled.   

Objectives of the Master Formula Record   

• To provide a standardized set of instructions for manufacturing each dosage form.
• To ensure batch-to-batch consistency and reproducibility of drug products.
• To maintain product quality, safety, and therapeutic efficacy.
• To comply with regulatory requirements such as GMP, ICH, USFDA, and WHO guidelines.
• To provide a permanent reference document for audits, inspections, and regulatory submissions.

• Contents of a Master Formula Record    

According to international regulatory agencies such as WHO and USFDA, an MFR must contain the following information:   

1. Product Information   

• Name of the product (brand name and generic name).   
• Dosage form (tablet, capsule, injection, etc.).   
• Strength of the product (e.g.,  Diclofenac  Sodium 100 mg SR).   
• Batch size (e.g., 100,000 tablets).   
• Description of the product.   

2. List of Ingredients   

• Name of active pharmaceutical ingredient (API).   
• Names of excipients (binders, fillers, disintegrants, lubricants, etc.).   
• Exact quantity of each ingredient per unit dose and per batch.   
• Specifications of raw materials (purity, grade, and quality requirements).   

3.  Instructions   

• Step-by-step details of the manufacturing process.   
• Sequence of mixing, granulation, drying, blending, compression, coating, or filling.   
• Critical process parameters (e.g., temperature, humidity, pressure, speed of equipment).   
• Special precautions to be taken during processing.   

4. Packaging Instructions   

• Type of packaging material to be used (blister packs, bottles, strips, etc.).   
• Quantity of packaging material required for each batch.   
• Printing and labeling instructions.   
• Storage conditions (temperature, humidity, protection from light).   

5. In-process Controls   

Tests to be performed during manufacturing such as weight variation, hardness, friability, and     dissolution.   

6. Finished Product Specifications   

• Description of the final product (appearance, colour, size, shape).   
• Physical and chemical specifications (assay, purity, uniformity).   
• Microbiological specifications (if applicable).   

7. Signatures and Approvals    

• Prepared by: Formulation scientist or production pharmacist.                                                                   
• Approved by: Head of Quality Assurance.                                                                                                       
• Date of approval. 

Batch Manufacturing Record (BMR)     

The Batch Manufacturing Record (BMR) is one of the most important documents in the pharmaceutical manufacturing process. It is a detailed, step-by-step document that records the actual history of the manufacturing of a specific batch of a pharmaceutical product. While the  Master Formula Record (MFR) provides the general blueprint or recipe, the BMR is the  practical execution document that records how a particular batch was manufactured based on that master formula.The Batch Manufacturing Record (BMR) is prepared for every batch manufactured and contains details such as batch number, lot numbers of raw materials, equipment used, operator signatures, and in-process control data. It ensures traceability of each batch and helps identify the source of errors in case of deviations.Every pharmaceutical company must maintain BMRs for all products and strengths manufactured, as per Good Manufacturing Practices (GMP) and regulatory requirements. It ensures traceability, accountability, and compliance, thereby protecting both the company and the patients consuming the medicine.    

Objectives of Batch Manufacturing Record 

• To provide documentary evidence of each step performed during manufacturing.
• To ensure that the product was manufactured strictly according to the approved Master Formula Record.
• To maintain traceability of raw materials, processing steps, and operators involved.
• To provide a reference during product recalls, complaints, or investigations.
• To demonstrate compliance with GMP and regulatory requirements.
• To serve as a legal document during audits and inspections.

Contents of a Batch Manufacturing Record    

According to regulatory guidelines, a BMR should contain the following information:  

1. General Information   

• Product name (brand and generic).   
• Dosage form (tablet, capsule, syrup, etc.).   
• Strength (e.g., Metformin Hydrochloride 500 mg SR).   
• Batch number.   
• Batch size (e.g., 200,000 tablets).   
• Date of manufacture and expiry.   

2. List of Raw Materials Used   

• Names of APIs and excipients.   
• Quantities weighed and used.   
• Reference to the raw material batch numbers.   
• Signatures of personnel who weighed and checked the materials.   

3. Manufacturing Instructions and Processing Steps   

• Detailed steps as per the MFR.   
• Equipment used with equipment ID numbers.   Time and date of each operation.   
• Signatures of the operator and supervisor.   
• In-process checks (e.g., blending uniformity, drying temperature, compression speed).

4. Packaging Details   

• Type of packaging material used (blister, bottle, strip).   
• Quantity of packaging material issued and used.   
• Labeling instructions.   
• Balance of unused packaging material and its reconciliation.   

5. In-Process Quality Control (IPQC) Results   

• Tests performed during manufacturing such as hardness, friability, weight variation, and dissolution.   
• Acceptance criteria and actual results obtained.   
• Signatures of quality control personnel.  

6. Yield Reconciliation  

• Expected yield as per MFR.    
• Actual yield obtained (both in-process and final yield).   
• Percentage yield.   
• Any deviations or losses during manufacturing.   

7. Signatures and Approvals    

• Prepared by (production operator).   
• Checked by (production supervisor).   
• Verified by (quality assurance officer).   
• Approved by (Head of QA).  

Drug Master File (DMF)  

A Drug Master File (DMF) is a confidential document submitted by manufacturers of Active Pharmaceutical Ingredients (APIs), excipients, or finished drug products to regulatory authorities such as the U.S. FDA. It contains comprehensive information on the chemistry, manufacturing processes, and quality control measures of a drug substance or component. DMFs are primarily used to provide regulatory authorities with detailed technical data while protecting proprietary information.

Role of DMF: 

• The Drug Master File (DMF) records the purity, potency, and identification of drugs in the Chemistry, Manufacturing & Controls (CMC) segment. 
• It aids in preparing registration or approval paperwork for drugs. 
• It safeguards confidential and proprietary information

Fig. Schematic representation of drug master file mechanism

Purpose of a DMF:

• Regulatory Support: Assists in the approval process for drugs by providing detailed Chemistry, Manufacturing, and Controls (CMC) information.
• Confidentiality: Protects sensitive manufacturing information and trade secrets from being disclosed to third parties.
• Collaboration: Enables multiple pharmaceutical companies to use the same API or intermediate without revealing proprietary processes.
• Internal Reference: Supports internal documentation, validation, and IND (Investigational New Drug) applications.

Types of DMFs:

DMFs are categorized based on the type of information they provide:

• Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel (rarely used now).
• Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation.
• Type III: Packaging Materials.
• Type IV: Excipients, Colorants, Flavorings or Materials Used in Drug Formulation.
• Type V: FDA-accepted reference information (any other information supporting CMC)

Contents of a DMF:

• Chemical Information: Structure, properties, and specifications of the drug substance or excipient.
• Manufacturing Process: Detailed description of synthesis, processing, in-process controls, and equipment.
• Quality Control: Analytical methods, specifications, impurity profiles, and stability data
• Packaging and Storage: Container-closure systems, labeling, and storage conditions.
• cGMP Compliance: Evidence of adherence to current Good Manufacturing Practices.

Importance of DMFs:

• Ensures consistency, quality, and safety of drug substances and products.
• Protects intellectual property while facilitating regulatory review.
• Streamlines drug development by avoiding duplication of technical data.
• Serves as a critical tool in global regulatory compliance, especially for multinational companies.

Standard Operating Procedures (SOPs)    

SOPs are detailed written instructions to perform specific processes consistently. In SR formulations, SOPs are required for critical steps like granulation, compression, coating, cleaning of equipment, and packaging. They ensure standardization and compliance with GMP.   In the pharmaceutical industry, Standard Operating Procedures (SOPs) are one of the most critical elements of documentation and quality management. An SOP is a written, step-by-step instruction that describes how to perform a particular task or operation in a consistent and controlled manner. It ensures that processes are carried out uniformly every time, regardless of who performs them, thereby minimizing errors and variations. Pharmaceutical manufacturing is a highly regulated industry where quality, safety, and compliance with Good Manufacturing Practices (GMP) are non-negotiable. Regulatory agencies such as the World Health Organization (WHO), US Food and Drug Administration (USFDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization   (CDSCO, India) mandate the preparation and use of SOPs in all pharmaceutical operations.SOPs act as the backbone of training, compliance, and quality control, serving as evidence during audits and inspections. Without approved SOPs, no activity in a pharmaceutical plant can be carried out legally or effectively.  

Objectives of SOPs   

• To ensure consistency and uniformity in all activities.   
• To minimize human errors and reduce variability.   
• To provide clear instructions for routine operations.   
• To train new employees and refresh existing staff on standard practices.   
• To comply with GMP and other regulatory requirements.   
• To serve as a reference document during internal and external audits.   
• To maintain product quality, patient safety, and company reputation.   

General Format of an SOP    

A typical pharmaceutical SOP includes the following sections:   

1. Title Page   

• SOP title (e.g., “Cleaning of Fluid Bed Dryer”).   
• SOP number and version.   
• Department name.   
• Effective date and review date.
• Prepared by, reviewed by, and approved by signatures.   

2. Objective

Clearly states the purpose of the SOP.

3. Scope

Defines the area of application (e.g., applicable in the granulation section of the production department).

4. Responsibilities

Lists the personnel responsible for performing, checking, and approving the activity.

5.Definitions (if required)

Provides meaning of technical terms used in the SOP.

6.Materials/Equipment Required

Specifies tools, raw materials, or instruments needed.

7. Procedure

Step-by-step description of the activity to be performed.

Includes precautions, critical control points, and acceptance criteria.

8. References: Cites related guidelines, regulations, or documents.

9. Annexures/Attachments

Includes forms, checklists, or flowcharts to support the SOP.

10 .Revision  History

Records details of any changes made in previous versions.

Types of SOPs in the Pharmaceutical Industry

SOPs are broadly classified into the following categories:

1.General SOPs

2.Production SOPs

3.Quality Control (QC) SOPs

4.Quality Assurance (QA) SOPs 

5.Safety and Environmental SOPs 

6.Engineering and Maintenance SOPs    7.Warehouse and Distribution SOPs

In-Process Testing Reports    

In pharmaceutical manufacturing, quality cannot be tested into a product; must be built into the product. This principle, highlighted by Good Manufacturing Practices (GMP), emphasizes that ensuring product quality is not limited to testing the final drug but also involves monitoring every stage of production. In-Process Quality Control (IPQC) refers to the checks and tests carried out during the manufacturing process, rather than after completion. These controls help to detect and correct errors at an early stage, preventing defective batches and ensuring uniform quality. IPQC is considered a critical component of the pharmaceutical quality system because it ensures that the finished product consistently meets its specifications. IPQC testing is documented in In-Process Testing Reports, which serve as proof that controls were performed and that the batch met required standards before further processing. In-process quality control (IPQC) is essential for maintaining batch uniformity.

Typical tests include:

• Weight variation   
• Hardness and friability   
• Content uniformity   
• Dissolution profile over 12–24 hours  

Objectives of In-Process Quality Control   

• To monitor the production process in real-time and ensure compliance with approved procedures.
• To identify and correct deviations during manufacturing before they affect the final product.
• To minimize batch failures, rework, and wastage.
• To ensure uniformity, safety, and efficacy of pharmaceutical products.
• To provide documentary evidence of compliance for audits and inspections.
• To maintain product quality and patient safety at all times.
• Parameters Checked During In-Process Quality Control
• IPQC varies depending on the dosage form. Below are the common tests:   

• 1.For Tablets 
• Weight Variation Test: Ensures uniformity in tablet weight.
• Hardness Test: Determines the mechanical strength of tablets.
• Friability Test: Assesses resistance to breaking or crumbling.
• Disintegration Test: Ensures tablets break down within the specified time.
• Thickness and Diameter: Checked using vernier calipers.
• Appearance: Tablets should be free from cracks, spots, or contamination.

2.For Capsules

• Weight Variation: Ensures uniform filling of capsules.
• Disintegration Time: Should fall within pharmacopeial limits.
• Moisture Content: Measured to prevent microbial growth.

3.For Liquids and Syrups

• pH Measurement: Ensures stability and palatability.
• Viscosity: Checked to ensure proper consistency.
• Appearance: Free from particulate matter.

4.For Injections (Parenteral)

• Clarity Test: Must be free from visible particles.
• pH and Osmolarity: Should be within safe physiological limits.
• Sterility Checks (preliminary): Ensures aseptic processing.
• Volume in Container: Ensures correct filling of vials or ampoules.

5.For Ointments and Creams

• Consistency: Smooth and uniform texture.
• pH Measurement: Must be skin-compatible.
• Spreadability: Checked for patient acceptability.
• Documentation: In-Process Testing Reports
• Every in-process check must be documented in an official In-Process Testing Report. This ensures traceability and accountability.

 A typical format includes:   

1.Product Details   

• Product name, dosage form, and strength.   
• Batch number and batch size.   
• Date and time of testing.   

2.Test Parameters and Specifications   

• Lists the in-process tests (e.g., hardness, friability, pH).   
• Provides reference limits as per pharmacopeia or MFR.  
• Records the actual test results obtained.   

4.Remarks    

Notes any deviations or special observations.   

 5.Signatures   

• Signed by production personnel performing the test.   
• Verified by Quality Control or Quality Assurance staff.      

Strategies for Effective IPQC    

• Regular training of production and QC staff.   
• Use of validated equipment and calibrated instruments.   
• Implementation of electronic data management systems (EDMS) for recording results.   
• Periodic internal audits to ensure compliance.   
• Strict supervision by QA at every stage of production.   

Stability Studies       

Stability studies are performed to evaluate the shelf life of formulations. Both accelerated stability studies (40°C/75% RH) and long-term stability studies (25°C/60% RH) are conducted. Reports are generated to ensure the release profile remains consistent throughout the product’s life cycle. Pharmaceutical products are expected to remain safe, effective, and of acceptable quality throughout their intended shelf life. However, drugs are chemical entities and may degrade over time due to factors such as temperature, humidity, light, and microbial contamination. To ensure that a drug product maintains its intended quality until its expiry date, stability studies are conducted. Stability studies are systematic investigations carried out to determine how the quality of a drug substance or drug product changes over time under the influence of various environmental factors. These studies help establish shelf life, storage conditions, and recommended packaging materials.   Regulatory bodies such as the International Council for Harmonisation (ICH), USFDA, WHO, and CDSCO (India) have issued detailed guidelines for conducting stability studies. These guidelines form the backbone of stability testing programs worldwide.   

Objectives of Stability Studies   

• To determine the shelf life (expiry date) of pharmaceutical products.   
• To recommend suitable storage conditions (e.g., “Store below 25 °C, protect from light”).   
• To select appropriate packaging materials that protect the product from degradation.   
• To evaluate the impact of environmental factors such as temperature, humidity, and light.   
• To ensure compliance with regulatory guidelines.   
• To guarantee patient safety by ensuring product quality throughout its lifecycle.   

Types of Stability Studies    

Stability studies are classified into several types depending on the conditions and objectives:    

1. Real-Time Stability Studies   

• Carried out under recommended storage conditions.   
• Provide actual data on product stability over the intended shelf life.   
• Time-consuming (can last 12–36 months).   

2. Accelerated Stability Studies   

• Conducted at higher stress conditions (e.g., higher temperature and humidity).    
• Provide quick data on degradation patterns.   
• Help predict shelf life within a short period.   

3. Intermediate Stability Studies   

• Conducted under conditions between real-time and accelerated studies.   
• Useful when accelerated studies show significant degradation.   

4. Stress Testing (Forced Degradation Studies)   

• Subject the drug to extreme conditions (heat, light, oxidation, acidic and basic environments).   
• Helps identify degradation products and pathways.   
• Provides data for developing stability-indicating analytical methods.   

5. Ongoing Stability Studies   

• Conducted after product approval and during commercial manufacturing.   
• Ensures that marketed batches remain stable until expiry. 

Factors Affecting Stability   

Stability of pharmaceutical products is influenced by several factors:   

• Temperature: Higher temperatures accelerate degradation reactions.   
• Humidity: Promotes hydrolysis, microbial growth, and physical changes.   
• Light: Causes photodegradation of light-sensitive drugs (e.g., nifedipine, riboflavin).   
• Oxygen: Leads to oxidative degradation of drugs like vitamin C.   
• pH of Formulation: Affects hydrolysis rate; e.g., esters degrade faster in alkaline pH.   
• Packaging Material: Poor packaging may allow moisture or oxygen ingress.   
• Formulation Excipients: Certain excipients may accelerate or retard degradation.  

Parameters Evaluated in Stability Studies    

• Stability testing involves monitoring various physical, chemical, and microbiological parameters over time:   
• Physical Parameters: Appearance, color, odor, dissolution rate, hardness (for tablets), viscosity (for liquids).   
• Chemical Parameters: Assay of active ingredient, degradation products, pH, preservative content.   
• Microbiological Parameters: Sterility (for injectables), microbial limits (for nonsterile products), preservative efficacy.   
• Functional Parameters: Drug release profile, performance of delivery system (e.g., inhalers). 

ICH Guidelines for Stability Studies   

The International Council for Harmonisation (ICH) has defined stability testing conditions based on climatic zones: